Pharmaceutical reimbursement is key to ensuring timely patient access and the sustainability of healthcare systems. The rise of therapeutic innovation, market competition, and personalized medicine has intensified pressure on health systems, highlighting the need to reassess reimbursement models to ensure resource efficiency and equitable access.
This study analyses the evolution of pharmaceutical pricing and reimbursement decisions in Spain over the past decade
through the Spanish Ministry of Health’s BIFIMED database.